Just to note that Agenus (AGEN) announced positive results in its Phase II trial for its Prophage vaccine treating glioblastoma multiforme, a form of brain cancer. The results are quite impressive. However, a larger, randomized Phase III trial will be needed to gain FDA approval, and that would take something like 3 years. Agenus is likely to partner with a larger company for the trial and commercialization of Prophage.
See the Agenus Prophage Results press release
I recently covered the broad range of therapies in the Agenus pipeline:
Agenus Platforms Provide Many Shots On Commercialization Goal May 13, 2014 at Seeking Alpha
Agenus stock closed at $3.22 yesterday and as I write has risen to $3.81, up 18%. That gives it a market capitalization of $237 million, which I think is still vastly undervalued given the pipeline.
I own Agenus stock, which I first acquired in October 2013, with my last purchase in April.